IDXX vs NVAX · P/E 40, rev $2.36B vs P/E 2.5, rev $196.2M
IDEXX Laboratories Inc (IDXX) versus Novavax Inc (NVAX) — a side-by-side from cached financials, not a winner call.
IDEXX Laboratories Inc (IDXX) is a diagnostics & research company listed on NASDAQ.
Novavax Inc (NVAX) is a biotechnology company listed on US.
Latest reported IDXX revenue for 2026-06-30 was $2.36B. Net income was $616.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
Latest reported NVAX revenue for 2026-06-30 was $196.2M. Net income was -$62.9M. Revenue was up 40.6% from 2026-03-31 to 2026-06-30. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
IDXX currently screens at market cap $43.08B and trailing P/E 40.2. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
Not investment advice. Open the IDXX and NVAX stock pages for the full models.
Not investment advice.